24th January 2022

$2.8m MRFF boost for vital cancer immunotherapy research

Mater Research will begin trialing a new targeted immunotherapy in 2022 to treat a rare but devastating blood cancer thanks to a $2.8m grant

Latest News

10 May 2021

FDA approval for new saliva oral and throat cancer diagnostic

Research by TRI-affiliated A/Prof Chamindie Punyadeera has led to the commercialisation of a new diagnostic.
More about FDA approval for new saliva oral and throat cancer diagnostic
16 April 2021

Potential New Treatment Could Help Save COVID-19 Patients

Anti-inflammatory drug, IC14, enters Phase II clinical trial to treat severely ill COVID-19 patients.
More about Potential New Treatment Could Help Save COVID-19 Patients
25 March 2021

US Department of Defense breast cancer grant

Dr Fernando Guimaraes has been awarded US$750K to progress a new breast cancer treatment
More about US Department of Defense breast cancer grant
24 March 2021

Breakthrough therapy cures lymphoma patient

A Mater Research team has cured a patient of a rare type of lymphoma
More about Breakthrough therapy cures lymphoma patient
24 March 2021

Anticancer and Antimicrobial peptide treatments

QUT's Dr Sónia Henriques, is developing selective and potent anticancer peptide-based treatments.
More about Anticancer and Antimicrobial peptide treatments
22 March 2021

New funding for COVID-19 research

Mater Research's TRI-based Dr Mitchell Sullivan has received funding for a COVID-19 research project.
More about New funding for COVID-19 research

Pages

Events

21 March 2022 9:30 AM6:00 PM

ASSC Genetics Summit 21 March 2022

The Australian Skin and Skin Cancer Research Centre (ASSC) is hosting the Genetics Summit
More about ASSC Genetics Summit 21 March 2022

Upcoming Events

Sorry, no results found

Please try again with less restrictive search criteria